Rigel entered into an exclusive license and supply agreement with Knight Therapeutics Inc. (Knight) in May 2022, to commercialize fostamatinib disodium hexahydrate (fostamatinib) in all potential indications in Latin America.
Rigel received an upfront cash payment, with the potential for additional regulatory and commercial milestones, and stepped-up royalties based on tiered net sales. In return, Knight receives exclusive rights to fostamatinib in all potential indications in Latin America.